Top-News
Ein Biotechnologielabor mit moderner Labortechnologie (Symbolbild).
Mittwoch, 26.04.2017 22:05 von | Aufrufe: 93

Amgen Reports First Quarter 2017 Financial Results

Ein Biotechnologielabor mit moderner Labortechnologie (Symbolbild). © Morsa Images / DigitalVision / Getty Images http://www.gettyimages.de

PR Newswire

THOUSAND OAKS, Calif., April 26, 2017

THOUSAND OAKS, Calif., April 26, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2017. Key results include:

  • Total revenues decreased 1 percent versus the first quarter of 2016 to $5.5 billion.
  • GAAP earnings per share (EPS) increased 12 percent to $2.79 driven by higher operating margins.
    • GAAP operating income increased 8 percent to $2.6 billion and GAAP operating margin increased 4 percentage points to 49.8 percent.
  • Non-GAAP EPS increased 9 percent to $3.15 driven by higher operating margins.
    • Non-GAAP operating income increased 5 percent to $3.0 billion and non-GAAP operating margin increased 3 percentage points to 57.6 percent.
  • 2017 EPS guidance increased to $10.64-$11.32 on a GAAP basis and $12.00-$12.60 on a non-GAAP basis; total revenues guidance unchanged at $22.3-$23.1 billion.
  • The Company generated $2.2 billion of free cash flow in the first quarter versus $1.8 billion in the first quarter of 2016.

"We are well positioned for the long term with our newer products demonstrating volume growth around the world and our tight operational expense management of the Company," said Robert A. Bradway, chairman and chief executive officer. "With robust Repatha® (evolocumab) outcomes data, we are working with payers to improve access to this important therapy for patients at risk for heart attacks and strokes."

$Millions, except EPS and percentages

Q1'17

Q1'16

YOY Δ







Total Revenues


ARIVA.DE Börsen-Geflüster

Werbung

Weiter aufwärts?

Kurzfristig positionieren in Amgen Inc.
UL6VAD
Ask: 0,15
Hebel: 7,82
mit moderatem Hebel
Zum Produkt
Smartbroker
UBS
Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: UL6VAD,. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.

Kurse

Amgen Inc.
268,97 $
+2,37%
Amgen Inc. Chart

$ 5,464

$ 5,527

(1%)

GAAP Operating Income

$ 2,591

$ 2,402

8%

GAAP Net Income

$ 2,071

$ 1,900

9%

GAAP EPS

$   2.79

$   2.50

12%

Non-GAAP Operating Income

$ 2,995

$ 2,859

5%

Non-GAAP Net Income

$ 2,333

$ 2,203

6%

Non-GAAP EPS

$   3.15

$   2.90

9%

References in this release to "non-GAAP" measures, measures presented "on a non-GAAP basis" and to "free cash flow" (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations.

Product Sales Performance

  • Total product sales decreased 1 percent for the first quarter of 2017 versus the first quarter of 2016.
  • Neulasta® (pegfilgrastim) sales increased 2 percent as favorable changes in accounting estimates and net selling price were offset partially by lower unit demand.
  • Enbrel® (etanercept) sales decreased 15 percent due to the impact of competition as well as lower rheumatology and dermatology segment growth compared to prior quarters.
  • Aranesp® (darbepoetin alfa) sales decreased 4 percent as higher unit demand was more than offset by unfavorable changes in foreign exchange rates, inventory and net selling price.
  • Prolia® (denosumab) sales increased 21 percent driven by higher unit demand.
  • Sensipar/Mimpara® (cinacalcet) sales increased 15 percent driven primarily by net selling price.
  • XGEVA® (denosumab) sales increased 6 percent driven by higher unit demand.
  • EPOGEN® (epoetin alfa) sales decreased 10 percent driven by net selling price.
  • KYPROLIS® (carfilzomib) sales increased 23 percent driven by higher unit demand.
  • Nplate® (romiplostim) sales increased 9 percent driven by higher unit demand.
  • NEUPOGEN® (filgrastim) sales decreased 31 percent driven primarily by the impact of competition.
  • Vectibix® (panitumumab) sales increased 2 percent driven by higher unit demand, offset partially by unfavorable changes in foreign exchange rates.
  • Repatha sales increased driven by higher unit demand.
  • BLINCYTO® (blinatumomab) sales increased 26 percent driven by higher unit demand.

 

Product Sales Detail by Product and Geographic Region

$Millions, except percentages

Q1'17

Q1'16

YOY Δ


US

ROW

TOTAL

TOTAL

TOTAL









Neulasta®

$1,048

$162

$1,210

$1,183

2%

Enbrel®

1,118

63

1,181

1,385

(15%)

Aranesp®

278

233

511

532

(4%)

Prolia®

279

146

425

352

21%

Sensipar® / Mimpara®

337

84

421

367

15%

XGEVA®

298

104

402

378

6%

EPOGEN®

270

0

270

300

(10%)

KYPROLIS®

137

53

190

154

23%

Nplate®

97

57

Werbung

Mehr Nachrichten zur Amgen Inc. Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News

PR Newswire Thumbnail
19.04.24 - PR Newswire
Redde Northgate Plc - Transaction in Own Shares
PR Newswire Thumbnail
19.04.24 - PR Newswire
Rightmove Plc - Holding(s) in Company
PR Newswire Thumbnail
19.04.24 - PR Newswire
UK Commercial Property REIT Ltd - Fourth Interim Dividend for 2023